AFJK
AFJK
Aimei Health Technology Co., LtdIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJK currently benefits from a simple, debt-free capital structure and access to public equity markets, while United Hydrogen brings an integrated hydrogen ecosystem, early positioning in an important growth market, diverse end-use applications, and a strong emphasis on innovation and partnerships. Together, they create a platform that could tap into multiple aspects of the energy transition if the merger proceeds as planned.
Key risks include AFJK’s lack of an operating business today, negative equity, and tight liquidity, as well as the heavy reliance on non-operating items for reported profit. On the operating side, United Hydrogen faces substantial execution, capital, technology, and policy risks in a volatile sector, compounded by the usual uncertainties around SPAC mergers, integration, market perception, and the need for ongoing funding to support large projects.
The near-term financial statements of AFJK are not very informative about long-term economics; the real outlook depends on whether the United Hydrogen merger closes and how effectively that business scales. If policy support for hydrogen remains strong and the company can deliver on its integrated, innovation-led strategy, growth potential is significant, but so is the uncertainty, with outcomes likely to vary widely depending on execution and external conditions.
About Aimei Health Technology Co., Ltd
https://www.aimeihealth.comAimei Health Technology Co., Ltd. currently lacks substantial business operations. Its core purpose is to pursue a strategic business combination, which may take the form of a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or a similar transaction with one or more companies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJK currently benefits from a simple, debt-free capital structure and access to public equity markets, while United Hydrogen brings an integrated hydrogen ecosystem, early positioning in an important growth market, diverse end-use applications, and a strong emphasis on innovation and partnerships. Together, they create a platform that could tap into multiple aspects of the energy transition if the merger proceeds as planned.
Key risks include AFJK’s lack of an operating business today, negative equity, and tight liquidity, as well as the heavy reliance on non-operating items for reported profit. On the operating side, United Hydrogen faces substantial execution, capital, technology, and policy risks in a volatile sector, compounded by the usual uncertainties around SPAC mergers, integration, market perception, and the need for ongoing funding to support large projects.
The near-term financial statements of AFJK are not very informative about long-term economics; the real outlook depends on whether the United Hydrogen merger closes and how effectively that business scales. If policy support for hydrogen remains strong and the company can deliver on its integrated, innovation-led strategy, growth potential is significant, but so is the uncertainty, with outcomes likely to vary widely depending on execution and external conditions.

CEO
Junheng Xie
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
KARPUS MANAGEMENT, INC.
Shares:1.03M
Value:$12.1M
FIRST TRUST CAPITAL MANAGEMENT L.P.
Shares:680K
Value:$8.02M
MIZUHO SECURITIES USA LLC
Shares:550.66K
Value:$6.5M
Summary
Showing Top 3 of 25

